A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Public ClinicalTrials.gov record NCT02612779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.
Study identification
- NCT ID
- NCT02612779
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2016 (Actual)
- Primary completion
- Jul 29, 2019 (Actual)
- Completion
- Jun 12, 2020 (Actual)
- Last update posted
- Jul 2, 2021
2016 – 2020
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center | Mobile | Alabama | 36607 | — |
| Sansum Clinic - USOR | Santa Barbara | California | 93105 | — |
| Colorado Blood Cancer Institute - PPDS | Denver | Colorado | 80218 | — |
| Rocky Mountain Cancer Centers (Williams) - USOR | Denver | Colorado | 80218 | — |
| Florida Cancer Specialists - EAST - SCRI - PPDS | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists - NORTH - SCRI - PPDS | St. Petersburg | Florida | 33705 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | — |
| Bay Hematology Oncology | Easton | Maryland | 21601 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Greenville Health System | Greenville | South Carolina | 29615 | — |
| Avera Health Care | Sioux Falls | South Dakota | 57105 | — |
| Jones Clinic PC | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology NASH - SCRI - PPDS | Nashville | Tennessee | 37203 | — |
| Texas Oncology (Loop) - USOR | San Antonio | Texas | 78217 | — |
| Virginia Cancer Specialists (Leesburg) - USOR | Leesburg | Virginia | 20176 | — |
| Swedish Medical Center | Seattle | Washington | 98104 | — |
| Cancer Care Northwest | Spokane Valley | Washington | 99216 | — |
| Aurora Health Care | Burlington | Wisconsin | 53105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02612779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02612779 live on ClinicalTrials.gov.